Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
MENLO PARK, Calif., March 01, 2017 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the Company is scheduled to present at two upcoming investor conferences. Details are as follows:
| Event: | Cowen & Co. 37th Annual Healthcare Conference |
| Date: | Tuesday, March 7, 2017 |
| Time: | 10:40 a.m. ET |
| Location: | The Boston Marriott Copley Place – Boston, MA |
| Event: | Barclays Global Healthcare Conference |
| Date: | Tuesday, March 14, 2017 |
| Time: | 3:50 p.m. ET |
| Location: | Loews Miami Beach Hotel – Miami, FL |
Audio webcasts of the Company’s presentations will be available on the investor relations section of the Versartis’ website at www.versartis.com. A replay of the presentation will be available for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes. For more information on Versartis, visit www.versartis.com.
Contacts: Corporate Communications: Christine Labaree Corporate Affairs (650) 600-1697 [email protected] Investors: David Burke Director, Investor Relations (650) 516-2703 [email protected]
